Optimising asthma care for patients and the planet

Our bold ambition is to eliminate asthma attacks and improve outcomes for patients, while at the same time reducing the environmental impact of asthma care.

Asthma is one of the most common chronic non-communicable diseases – it affects approximately 262 million people globally and is responsible for over 450,000 deaths each year worldwide, most of which are preventable.^1,2 Further, an estimated 136 million exacerbations are experienced globally every year.³ These numbers tell us that asthma is a serious and often poorly managed condition, and that many are living with asthma that is uncontrolled.

This year, the Global Initiative for Asthma (GINA) emphasised the need to empower people with asthma with the appropriate education to manage their disease, and to recognise when to seek medical help as part of their “Asthma Education Empowers” World Asthma Day campaign.⁴ At AstraZeneca, we are steadfast in our commitment to work alongside the global respiratory community in driving education and awareness among patients, healthcare professionals and policymakers on the key issues affecting people with asthma, including under- or inaccurate diagnosis, inappropriate medicines use and poor recognition of patients requiring specialist assessment and further management.⁴ We have a bold ambition to help eliminate asthma attacks and improve outcomes for patients, while at the same time reducing the environmental impact of asthma care.⁵

Our collaboration with the International Primary Care Respiratory Group on Asthma Right Care – a global social movement aimed at disrupting the status quo in asthma care – is an example of this commitment. The programme, now launched in 24 countries around the world, equips general practitioners (GPs), pharmacists, nurses, patients and others involved in front-line care with the tools needed to seek better asthma management solutions and, in the process, improve outcomes for people with asthma.⁶

We also contribute to initiatives that address the structural and policy gaps in health systems. Severe asthma is a distinct and debilitating condition representing up to 10% of asthma cases⁷ yet accounts for at least 50% of the total costs of asthma^8,9 and 10 times that of mild asthma, based on a Canadian study.¹⁰ A lack of awareness of what appropriate care should be for people with severe asthma means that patients often face delays in diagnosis and referral.^7,11 We have supported the development of health system quality standards in severe asthma which have served as blueprints for improving referral pathways, securing appropriate specialist resources and increasing use of guideline directed care.¹²

Well-controlled asthma combines benefits both for patients and for the carbon footprint of care

The climate crisis, pollution and other environmental factors contribute to the burden of chronic respiratory diseases including asthma.^13,14 At the same time, caring for millions of people with these conditions carries an environmental impact.¹⁵

Respiratory diseases like asthma are complex, difficult to treat and often poorly controlled,^16,17 and are associated with a greater carbon footprint of care.^15,18 In the UK, Europe and the US, asthma is poorly controlled in around half of those with the condition.^15,19 Among asthma patients in low to middle income countries, this number rises to an alarming 90%, substantially increasing the risk of hospital admission and severe illness as well as healthcare costs.²⁰ Poorly controlled asthma is associated with increased morbidity and healthcare resource utilisation.¹⁵ Optimising care by implementing evidence-based guidelines into clinical practice can reduce exacerbations, and the improved patient outcomes may also decrease the overall carbon footprint associated with asthma care.^15,21,22  

We’re committed to advancing asthma care through partnership and innovation

As leaders in respiratory care our work to improve outcomes in order to decarbonise the footprint of care is coupled with our commitment to reduce the carbon footprint of our medicines. Recently, we have accelerated the development of our inhaled respiratory medicines using an innovative, next-generation propellant with near-zero global warming potential (99.9% lower than in today’s medicines).⁵ First launches are anticipated from 2025 onwards, subject to regulatory approvals.

References

1. Global Asthma Network. The Global Asthma Report 2022. [Online]. Available at: http://globalasthmareport.org/resources/Global_Asthma_Report_2022.pdf. Accessed May 2024.
2. WHO/Asthma. Available at: https://www.who.int/news-room/fact-sheets/detail/asthma. Accessed May 2024.   
3. AstraZeneca Pharmaceuticals. Data on File. Budesonide/formoterol Data on File: Annual Rate of Asthma Exacerbations Globally. (REF-173201).
4. GINA World Asthma Day. [Online]. Available at: ginaasthma.org/world-asthma-day-may-7-2024/. Accessed May 2024.
5. AstraZeneca. [Online]. AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next- generation respiratory inhalers. Available at: AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers. Accessed May 2024.
6. Asthma Right Care. IPCRG, 9 Oct. 2023. [Online]. Available at: www.ipcrg.org/asthmarightcare. Accessed May 2024.
7. Hekking PW, Wener RR, Amelink M, et al. 2015. The prevalence of severe refractory asthma. J Allergy Clin Immunol 135(4): 896-902
8. Meyers J, Yoo J, Reddel H. 2019. Difficult-to-treat and severe asthma in adults: Towards a new treatment paradigm. Australian Journal for General Practitioners 48: 188-92
9. Bahadori K, Doyle-Waters MM, Marra C, et al. 2009. Economic burden of asthma: a systematic review. BMC Pulmonary Medicine 9(1): 24
10. Sadatsafavi M, Lynd L, Marra C. 2010. Direct health care costs associated with asthma in British Columbia. Can Respir J 17(2): 74-80
11. Chung KF, Wenzel SE, Brozek JL, et al. 2014. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43(2): 343-73 
12. Haughney J, Winders TA, Holmes S, et al. 2020. Global quality standard for identification and management of severe asthma. Advances in Therapy 37(9): 3645-59
13. WHO. Climate change and health. [Online]. Available at:https://www.who.int/news-room/fact-sheets/detail/climate-change-and-health. Accessed May 2024.
14. WHO. Ambient (outdoor) air pollution. [Online]. Available at: https://www.who.int/news-room/fact-sheets/detail/ambient-(outdoor)-air-quality-and-health. Accessed May 2024.
15. Wilkinson et al., Greenhouse gas emissions associated with suboptimal asthma care in the UK: the SABINA healthCARe‒Based envirONmental cost of treatment (CARBON) study. Thorax. 2024 Feb 27;79(5):412-421.
16. Global Initiative for Asthma. [Online]. Global strategy for asthma management and prevention, 2023. Available at: https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf. Accessed May 2024.
17. Eurostat. Respiratory diseases statistics. [Online]. Available at: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Respiratory_diseases_%20statistics&oldid=497079#Deaths_from_diseases_of_the_respiratory_system. Accessed May 2024.
18. ARUP. Health care’s climate footprint. [Online]. Available at: https://www.arup.com/perspectives/publications/research/section/healthcares-climate-footprint. Accessed May 2024.
19. Yaghoubi M et al., The Projected Economic and Health Burden of Uncontrolled Asthma in the Unites States. American Journal Respiratory Critical Care Med. 2019 Nov; 200(9): 1102-1112.
20. Mortimer, Kevin et al. “Asthma management in low and middle income countries: case for change.” The European respiratory journal vol. 60,3 2103179. 15 Sep. 2022, doi:10.1183/13993003.03179-2021
21. SMI. Decarbonising patient care pathways. [Online]. Available at: https://a.storyblok.com/f/109506/x/88fe7ea368/smi-hstf-pcp-whitepaper.pdf. Accessed May 2024
22. Usmani OS, Levy ML. Effective respiratory management of asthma and COPD and the environmental impacts of inhalers. NPJ Prim Care Respir Med. 2023;33(1):24.

Veeva ID: Z4-65352
Date of preparation: May 2024